Stock Analiz

Sutro Biopharma, Inc. STRO

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026

$9.82Market cap $163M
Open the interactive analysis →

Sutro Biopharma, Inc. (STRO) is a healthcare company listed in the US with a market value of about $163M. In the twelve months to September 30, 2026 it had revenue of $45M and net income of -$155M, a net margin of -344.2%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 19% a year, a 5-year average ROIC of -97%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 97% below the current price.

About Sutro Biopharma

Sutro Biopharma is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2018. Revenue went from $60M in 2016 to $102M in 2025, growth of about 6.2% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 66% over three years (dilution for shareholders). It spends 162% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth4/5
Track record2/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.6
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−97%

Growth and quality

Revenue growth (1 yr)65.2%
Revenue growth (5 yrs, per year)19.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-193.8%
ROIC (5-yr avg.)-96.6%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$45M$102M$62M$154M$68M$62M$43M$43M$38M$52M$60M
Net income-$155M-$191M-$227M-$107M-$119M-$106M-$32M-$119M-$35M-$20M$2M
Free cash flow————————$11M-$40M-$18M
EPS (diluted)$-12.63$-22.49$-29.40$-17.68$-23.34$-22.74$-9.83$-24.13$-60.87$-436.44$0.00
Net margin-344.2%-186.5%-366.6%-69.5%-175.9%-170.6%-75.2%-278.9%-91.9%-38.0%2.9%
ROIC——-278.0%-38.5%-38.1%-31.8%-14.5%-40.7%-20.1%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 13 analysts is $44.62, 354% above the current price; targets range from $10.00 to $61.00; the consensus rating is “Strong buy”; expected EPS is $-6.22 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Sutro Biopharma stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 97% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Sutro Biopharma pay a dividend?

Not currently.

Is Sutro Biopharma a good stock to buy?

We do not give buy or sell advice. Sutro Biopharma scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.